Literature DB >> 21159603

Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

William H Gmeiner1, William C Reinhold, Yves Pommier.   

Abstract

A profile of microRNA (miRNA) and mRNA expression patterns across the NCI-60 cell-line screen was analyzed to identify expression signatures that correlate with sensitivity to FdUMP[10], fluorouracil (5FU), floxuridine (FdU), topotecan, and irinotecan. Genome-wide profile analyses revealed FdUMP[10] resembles FdU most closely and shows dissimilarities with 5FU. FdUMP[10] had the largest dynamic range of any of these drugs across the NCI-60 indicative of cancer cell-specific activity. Genes involved in endocytosis, such as clathrin (CLTC), SNF8, annexin A6 (ANXA6), and amyloid protein-binding 2 (APPBP2) uniquely correlated with sensitivity to FdUMP[10], consistent with a protein-mediated cellular uptake of FdUMP[10]. Genes involved in nucleotide metabolism were enriched for the three fluoropyrimidine drugs, with the expression profile for 5FU correlated to an RNA-mediated cytotoxic mechanism, whereas expression of glycosyltransferases (XYLT2) that use UDP sugars as substrates and the nucleoside diphosphatase and metastasis suppressor NM23 (NME1) were associated with FdUMP[10] sensitivity. Topotecan and irinotecan had significant negative correlations with miR-24, a miRNA with a high aggregate P(CT) score for topoisomerase 1 (Top1). Our results reveal significant new correlations between FdUMP[10] and Top1 poisons, as well as new information on the unique cytotoxic mechanism and genomic signature of FdUMP[10]. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159603      PMCID: PMC3059097          DOI: 10.1158/1535-7163.MCT-10-0674

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  36 in total

1.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

2.  A gene expression database for the molecular pharmacology of cancer.

Authors:  U Scherf; D T Ross; M Waltham; L H Smith; J K Lee; L Tanabe; K W Kohn; W C Reinhold; T G Myers; D T Andrews; D A Scudiero; M B Eisen; E A Sausville; Y Pommier; D Botstein; P O Brown; J N Weinstein
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

3.  The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells.

Authors:  O H Temmink; M de Bruin; A C Laan; A W Turksma; S Cricca; A J Masterson; P Noordhuis; G J Peters
Journal:  Int J Biochem Cell Biol       Date:  2006-05-09       Impact factor: 5.085

4.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

Authors:  K D Paull; R H Shoemaker; L Hodes; A Monks; D A Scudiero; L Rubinstein; J Plowman; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

Review 5.  Novel chemical strategies for thymidylate synthase inhibition.

Authors:  W H Gmeiner
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

6.  COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition.

Authors:  Daniel W Zaharevitz; Susan L Holbeck; Christopher Bowerman; Penny A Svetlik
Journal:  J Mol Graph Model       Date:  2002-01       Impact factor: 2.518

7.  Stochastic models inspired by hybridization theory for short oligonucleotide arrays.

Authors:  Zhijin Wu; Rafael A Irizarry
Journal:  J Comput Biol       Date:  2005 Jul-Aug       Impact factor: 1.479

8.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Authors:  Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

9.  Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.

Authors:  Akira Hirasawa; Fumiko Saito-Ohara; Jun Inoue; Daisuke Aoki; Nobuyuki Susumu; Tetsuji Yokoyama; Shiro Nozawa; Johji Inazawa; Issei Imoto
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

10.  Enhanced DNA-directed effects of FdUMP[10] compared to 5FU.

Authors:  William H Gmeiner; Eric Trump; Cui Wei
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004       Impact factor: 1.381

View more
  50 in total

Review 1.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

Review 2.  Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Authors:  William C Reinhold; Margot Sunshine; Sudhir Varma; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-06-05       Impact factor: 12.531

3.  All-atom MD indicates ion-dependent behavior of therapeutic DNA polymer.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2017-08-23       Impact factor: 3.676

4.  The NCI-60 Methylome and Its Integration into CellMiner.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Vinodh Rajapakse; Augustin Luna; Kurt W Kohn; Holly Stevenson; Yonghong Wang; Holger Heyn; Vanesa Nogales; Sebastian Moran; David J Goldstein; James H Doroshow; Paul S Meltzer; Manel Esteller; Yves Pommier
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

5.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Authors:  Timothy S Pardee; Evan Gomes; Jamie Jennings-Gee; David Caudell; William H Gmeiner
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

6.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Authors:  William C Reinhold; Margot Sunshine; Hongfang Liu; Sudhir Varma; Kurt W Kohn; Joel Morris; James Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2012-07-15       Impact factor: 12.701

Review 7.  F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death.

Authors:  William H Gmeiner; Patricia J Gearhart; Yves Pommier; Jun Nakamura
Journal:  Future Oncol       Date:  2016-06-22       Impact factor: 3.404

8.  All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2016-09-21       Impact factor: 2.991

9.  Cooperative stabilization of Zn(2+):DNA complexes through netropsin binding in the minor groove of FdU-substituted DNA.

Authors:  Supratim Ghosh; Freddie R Salsbury; David A Horita; William H Gmeiner
Journal:  J Biomol Struct Dyn       Date:  2012-11-16

10.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.